GHK-Cu Injections in Aesthetic Medicine: What Does the Evidence Mean for South African Practitioners?
Injectable copper peptides are attracting growing interest in aesthetic medicine, regenerative treatments and longevity. But what does the evidence actually tell us, and what should South African practitioners consider before using or recommending them?
Copper peptides, particularly glycyl-L-histidyl-L-lysine copper (GHK-Cu), have gained considerable attention in aesthetic medicine. They are discussed in connection with skin quality, collagen production, wound healing, hair growth, recovery and so-called longevity treatments.
The interest is understandable. GHK-Cu has a biologically interesting profile and has been investigated for its potential role in tissue remodelling, collagen synthesis and regenerative processes.
But an important distinction needs to be made:
Evidence that a molecule has interesting biological activity is not the same as evidence that injecting it into patients is safe and effective.
For South African practitioners, there is another layer to consider: regulatory status and the source of the product being administered.
What is GHK-Cu?
GHK, or glycyl-L-histidyl-L-lysine, is a naturally occurring tripeptide with an affinity for copper. It has been studied for its possible involvement in processes including wound healing, extracellular matrix remodelling and collagen production.
Much of the interest surrounding copper peptides has historically centred on topical skincare.
However, topical copper peptide products and injectable GHK-Cu are not interchangeable.
Changing the route of administration changes the biological exposure, and therefore changes the questions that need to be answered about dose, pharmacology, safety and efficacy.
Research into topical copper peptides therefore cannot simply be used to establish the safety or effectiveness of systemic or subcutaneous GHK-Cu.
Does injectable GHK-Cu have established clinical evidence?
The evidence for injectable GHK-Cu remains limited.
There is biological and preclinical research suggesting potentially interesting effects involving collagen, extracellular matrix processes and tissue repair. However, these findings do not establish injectable GHK-Cu as a clinically proven treatment for skin rejuvenation, hair growth, systemic anti-ageing or recovery.
This distinction is important in aesthetic medicine.
A plausible mechanism can provide a reason to investigate a treatment. It does not, on its own, establish:
whether the treatment produces a meaningful clinical benefit
the appropriate dose
the appropriate treatment frequency
which patients may benefit
the short- and long-term safety profile
whether the benefits outweigh the risks
For practitioners, the important question is therefore not simply “Could GHK-Cu work?”
It is “What human clinical evidence demonstrates that injectable GHK-Cu works, at what dose, for which indication, and with what risks?”
Why are injectable peptides receiving so much attention?
The growing interest in injectable peptides reflects a wider trend in aesthetic and longevity medicine.
Patients can now encounter information about peptides through social media, podcasts, online communities and longevity-focused platforms. Products may also be commercially available through online suppliers or informal channels.
Availability, however, should not be confused with regulatory approval or clinical validation.
A product being available for purchase does not establish that it has been evaluated for the indication for which it is being promoted.
What does SAHPRA say about peptide products?
This is particularly relevant in South Africa.
The South African Health Products Regulatory Authority (SAHPRA) has warned about the increasing availability and use of unregistered peptide products in South Africa. SAHPRA states that such products are being sold through online platforms, social media, gyms, wellness centres and informal suppliers.
SAHPRA's warning includes concerns about products that have not been evaluated and approved for safety, quality and efficacy. It also highlights risks associated with injectable products, including infection, harmful interactions, contamination and unknown long-term effects.
For practitioners, this means that the regulatory status and provenance of an injectable product should be considered alongside the scientific evidence.
Is “research grade” the same as approved for human use?
No.
The terminology used by suppliers can sometimes create confusion.
Descriptions such as “research peptide”, “research use only”, “biohacking peptide” or similar terminology do not, by themselves, establish that a product has been authorised for administration to human patients.
SAHPRA states that products intended to treat, prevent or alter bodily functions are subject to the regulatory requirements of the Medicines and Related Substances Act, 1965.
South Africa's regulatory framework requires consideration of the quality, safety and efficacy of medicines. SAHPRA's current clinical guidance states that the Authority may require information necessary to establish these aspects of a medicine.
This makes product sourcing particularly important when considering injectable peptides.
What about products obtained from overseas suppliers?
An overseas supplier, international website or product that is available in another country does not automatically establish that the same product is authorised for use in South Africa.
Practitioners should consider the specific product, its intended use, its regulatory status in South Africa, its manufacturer and supply chain, as well as the evidence supporting its proposed indication.
SAHPRA maintains resources for checking registered health products and other regulatory information.
What are the safety questions?
One of the difficulties with injectable GHK-Cu is that the evidence base does not provide the same level of certainty that practitioners would want when introducing an established medical treatment.
Questions remain around appropriate dosing, frequency, systemic exposure and longer-term safety.
Injecting any substance also introduces risks that are not present in the same way with topical application.
These include considerations around:
sterility
contamination
product identity and purity
manufacturing consistency
storage and handling
injection-related complications
immune reactions
interactions with other treatments
unknown systemic effects
The fact that GHK occurs naturally in the human body should not be interpreted as proof that administering concentrated GHK-Cu by injection is automatically safe.
“Natural” and “safe to inject” are not synonymous.
What about the argument that GHK levels decline with age?
One argument sometimes used to support GHK supplementation is that circulating GHK may decline with age.
However, a biological change associated with ageing does not automatically mean that it represents a deficiency requiring supplementation.
To establish that correcting such a change improves health or aesthetic outcomes, clinical research would need to demonstrate a meaningful benefit from intervention.
Without that evidence, the biological observation remains a hypothesis rather than proof of a therapeutic indication.
What about topical copper peptides?
This is where practitioners and patients need to make a clear distinction.
Topical copper peptide skincare has a much longer history of cosmetic use than injectable GHK-Cu.
There is research investigating topical copper peptides in areas including fibroblast activity, collagen synthesis, extracellular matrix remodelling and antioxidant activity.
However, even topical research needs to be interpreted carefully. Laboratory or mechanistic findings do not necessarily translate into measurable clinical outcomes in a finished cosmetic formulation.
Most importantly:
Evidence for topical copper peptides cannot simply be extrapolated to injectable GHK-Cu.
The route of administration, dose, exposure and risk profile are fundamentally different.
What should practitioners ask before considering an injectable peptide?
For practitioners, a useful approach is to separate the questions into four areas.
1. What is the indication?
What specific clinical problem is the treatment intended to address?
Is the proposed indication supported by human clinical evidence?
2. What is the evidence?
Is there peer-reviewed human research?
Are there appropriately designed clinical trials?
Are clinically meaningful outcomes being measured?
Is the evidence specific to the injectable product and route of administration?
3. What is the product?
Where was it manufactured?
What is its pharmaceutical quality?
How is sterility assured?
What documentation is available regarding identity, purity and manufacturing?
What is its regulatory status in South Africa?
4. What are the risks?
What adverse effects have been documented?
What is known about longer-term use?
Are there contraindications or potential interactions?
What happens if a complication occurs?
These questions are particularly important when a treatment is being promoted through commercial or social media channels faster than the clinical evidence is developing.
What should patients tell their practitioner?
Patients may not always consider peptide use relevant when completing an aesthetic medical history.
Practitioners may therefore want to ask specifically about:
injectable peptides
compounded or non-standard injectable products
products purchased online
longevity or “anti-ageing” protocols
supplements and performance-enhancing substances
treatments received outside conventional medical settings
The purpose is not to dismiss the patient's interest.
It is to establish an accurate clinical history and understand what substances the patient may already be using.
Where does this leave injectable GHK-Cu?
The current evidence does not justify treating injectable GHK-Cu as an established aesthetic or anti-ageing therapy simply because the molecule has promising biological properties.
That does not mean GHK-Cu is scientifically uninteresting.
On the contrary, its biological effects warrant continued investigation.
But there is a difference between a promising research area and an established treatment.
For South African practitioners, that distinction should be considered alongside the regulatory status of the specific product.
SAHPRA's current warning about unregistered peptide products makes this particularly relevant.
The bottom line
GHK-Cu is an interesting molecule with a developing scientific literature, but the evidence for injectable GHK-Cu in aesthetic medicine remains limited.
The evidence supporting topical copper peptides should not automatically be transferred to injectable use.
For South African practitioners, scientific evidence and regulatory considerations need to be considered together. A product being commercially available, discussed online or used by practitioners does not, by itself, establish that it has been evaluated and authorised for the proposed clinical indication.
As aesthetic medicine continues to adopt new technologies and treatments, the challenge is not to reject innovation, but to distinguish biological plausibility, emerging evidence and established clinical practice.
For practitioners, patients and the industry, that distinction matters.
Comments